Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 16 de 16
1.
Neurol Sci ; 38(4): 635-642, 2017 Apr.
Article En | MEDLINE | ID: mdl-28078569

Decreased information processing speed (IPS) is frequently reported in pediatric multiple sclerosis (MS) patients. The computerized version of the Symbol Digit Modalities Test (c-SDMT) measures IPS over eight consecutive trials per session and additionally captures changes in performance within the session. Here, we establish normative c-SDMT performance and test-retest reliability in healthy children (HC) and explore differences in the overall c-SDMT-performance between HC and MS patients. This cross-sectional study included 478 HC (237 female, 49.5%) divided into five age groups (2 years each), and 27 MS patients (22 female, 81.5%) aged 8-18 years. The average time to complete the c-SDMT increased with age (|r| 0.70, 95% CI -0.74, -0.64). Test-retest reliability was high (ICC = 0.91) in HC. The total time to complete the c-SDMT did not differ between children with MS and sex- and age- matched HC (p = 0.23). However, MS patients were less likely to show faster performance across all the successive eight trials compared to HC (p = 0.0001). Healthy children demonstrate faster IPS with increasing age, as well as during successive trials of the c-SDMT. The inability of pediatric MS patients to maintain the increase in processing speed over successive trials suggests a reduced capacity for procedural learning, possibly resulting from cognitive fatigue.


Cognition Disorders/diagnosis , Diagnosis, Computer-Assisted , Multiple Sclerosis/psychology , Neuropsychological Tests , Adolescent , Child , Cognition Disorders/etiology , Computers , Cross-Sectional Studies , Female , Humans , Male , Multiple Sclerosis/complications , Psychology, Child , Reference Values , Reproducibility of Results , Time Factors
2.
Neuroradiology ; 58(10): 1035-1042, 2016 Oct.
Article En | MEDLINE | ID: mdl-27516098

INTRODUCTION: Infantile neuroaxonal dystrophy (INAD), an autosomal recessive neurodegenerative disorder due to PLA2G6 mutation, is classified both as a PLA2G6-associated neurodegeneration (PLAN) disorder and as one of the neurodegeneration with brain iron accumulation (NBIA) disorders. Age of onset and clinical presentation in INAD is variable. Typically described imaging features of cerebellar atrophy, cerebellar cortex bright FLAIR signal, and globus pallidus iron deposition are variable or late findings. We characterize clinical and neuroimaging phenotypes in nine children with confirmed PLA2G6 mutations and show a useful imaging feature, clava hypertrophy, which may aid in earlier identification of patients. Measurements of the clava confirm actual enlargement, rather than apparent enlargement due to volume loss of the other brain stem structures. METHODS: A retrospective clinical and MRI review was performed. Brain stem measurements were performed and compared with age-matched controls. RESULTS: We identified nine patients, all with novel PLA2G6 gene mutations. MRI, available in eight, showed clava hypertrophy, regardless of age or the absence of other more typically described neuroimaging findings. Brain autopsy in our cohort confirmed prominent spheroid bodies in the clava nuclei. CONCLUSION: Clava hypertrophy is an important early imaging feature which may aid in indentification of children who would benefit from specific testing for PLA2G6 mutations.


Biometry/methods , Group VI Phospholipases A2/genetics , Magnetic Resonance Imaging/methods , Neuroaxonal Dystrophies/genetics , Neuroaxonal Dystrophies/pathology , Child, Preschool , Diagnosis, Differential , Female , Genetic Predisposition to Disease/genetics , Humans , Hypertrophy , Infant , Male , Neuroaxonal Dystrophies/diagnostic imaging , Reproducibility of Results , Sensitivity and Specificity
3.
Arch Clin Neuropsychol ; 27(5): 495-509, 2012 Aug.
Article En | MEDLINE | ID: mdl-22751624

Executive functions (EFs) are vulnerable to disruption in pediatric-onset multiple sclerosis (MS) patients. We describe the pattern and correlates of executive dysfunction in 34 adolescents with MS on neuropsychological tests and the parent version of the Behavior Rating Inventory of Executive Function (BRIEF). The adolescents with MS performed lower than age-matched controls in several areas of executive functioning, with 44% of patients being impaired on the Trail Making Test-Part B. On the BRIEF, problems in working memory and planning/organization were identified in the patient group compared with controls, particularly in patients with a younger age at disease onset. Task performance and parent-ratings of EF skills were strongly related to whole brain and regional brain volume metrics and, to a lesser extent, T(2)-weighted lesion volume. Working memory and attention switching are at greatest risk of impairment. Results support the inclusion of neuropsychological assessment alongside parent-report measures of EF skills in childhood-onset MS.


Brain/pathology , Executive Function , Multiple Sclerosis/psychology , Nerve Fibers, Myelinated/pathology , Adolescent , Age Factors , Attention , Child , Female , Humans , Intelligence , Magnetic Resonance Imaging , Male , Memory, Short-Term , Multiple Sclerosis/pathology , Neuroimaging , Neuropsychological Tests , Predictive Value of Tests , Young Adult
4.
Mult Scler ; 18(8): 1170-80, 2012 Aug.
Article En | MEDLINE | ID: mdl-22291032

BACKGROUND: Multiple sclerosis (MS) onset during adolescence has the potential to disrupt a key period of psychosocial maturation. OBJECTIVE: We aimed to examine the prevalence and risk factors associated with emotional and behavioral outcomes in adolescents with MS. METHODS: The Behavioral Assessment System for Children-2nd Edition (BASC-2) was completed by 31 adolescents with MS (mean age = 16.1 years), 31 age-matched controls, and parents of all participants. BASC-2 outcomes were compared between groups. Base rates were examined for scores falling at least one or two standard deviations below norm. Associations between BASC-2 outcomes and features of disease severity and IQ were examined. RESULTS: Youth with MS were reported by their parents to have more symptoms of depression and somatization and lower adaptive skills compared with reports by parents of controls. On the self-report, patients endorsed more problems of inattention/hyperactivity and lower self-reliance relative to controls. Behavioral concerns and reduced adaptive functioning in the MS group were associated with fatigue, poor relations with parents, and perceived social stress. Psychosocial outcomes did not associate with number of relapses, Expanded Disability Status Scale score, disease duration, brain lesion volume or IQ. CONCLUSION: Youth with MS are at risk of difficulties in behavioral and emotional health. Relations with parents emerged as a key factor influencing the emotional well-being of youth with MS, suggesting an important role for family-centered care in this population.


Adolescent Behavior , Emotions , Mental Disorders/psychology , Mental Health , Multiple Sclerosis/psychology , Adaptation, Psychological , Adolescent , Age Factors , Analysis of Variance , Attention Deficit Disorder with Hyperactivity/epidemiology , Attention Deficit Disorder with Hyperactivity/psychology , Case-Control Studies , Chi-Square Distribution , Child , Cross-Sectional Studies , Depression/epidemiology , Depression/psychology , Disability Evaluation , Female , Humans , Intelligence , Intelligence Tests , Magnetic Resonance Imaging , Male , Mental Disorders/diagnosis , Mental Disorders/epidemiology , Multiple Sclerosis/diagnosis , Multiple Sclerosis/epidemiology , Ontario/epidemiology , Parent-Child Relations , Predictive Value of Tests , Prevalence , Psychiatric Status Rating Scales , Risk Assessment , Risk Factors , Severity of Illness Index , Social Behavior , Somatoform Disorders/epidemiology , Somatoform Disorders/psychology , Young Adult
5.
Neuropsychology ; 25(3): 319-32, 2011 May.
Article En | MEDLINE | ID: mdl-21534686

OBJECTIVE: Brain MRI measures were correlated with neuropsychological function in 35 pediatric-onset multiple sclerosis (MS) patients and 33 age- and sex-matched healthy controls. METHOD: Mean age of MS patients was 16.3 ± 2.3 years with average disease duration of 4.3 ± 3.1 years. Cortical gray matter, thalamic, and global brain volumes were calculated for all participants using a scaling factor computed using normalization of atrophy method to normalize total and regional brain volumes for head size. T1- and T2-weighted lesion volumes were calculated for MS patients. RESULTS: Cognitive impairment (CI) was identified in 29% of the MS cohort. Cognitive deficits predominantly involved attention and processing speed, expressive language, and visuomotor integration. Relative to controls, the MS group showed significantly lower thalamic volume (p < .001), total brain volume (p < .008), and gray matter volume (p < .015). Corpus callosum area and thalamic volume differentiated patients identified as having CI from those without CI (p < .05). Regression models controlling for disease duration and age indicated that thalamic volume accounted for significant incremental variance in predicting global IQ, processing speed, and expressive vocabulary (ΔR2 ranging from .43 to .60) and was the most robust MRI predictor of cognition relative to other MRI metrics. CONCLUSIONS: The robust association between cognitive function and reduced size of thalamus and global brain volume in pediatric-onset MS patients implicate neurodegenerative processes early in the disease course, and suggest that plasticity of an immature central nervous system is not sufficient to protect patients from the deleterious consequences of MS on cognitive neural networks. (PsycINFO Database Record (c) 2011 APA, all rights reserved).


Brain/pathology , Cognition , Magnetic Resonance Imaging , Multiple Sclerosis/pathology , Multiple Sclerosis/psychology , Adolescent , Age of Onset , Case-Control Studies , Corpus Callosum/pathology , Female , Humans , Male , Multiple Sclerosis/diagnosis , Organ Size , Severity of Illness Index , Thalamus/pathology
6.
Neurology ; 72(24): 2076-82, 2009 Jun 16.
Article En | MEDLINE | ID: mdl-19439723

OBJECTIVE: To review our multicenter experience with cyclophosphamide in the treatment of children with multiple sclerosis (MS). METHODS: Retrospective chart review of children with MS treated with cyclophosphamide. Demographic, clinical, treatment, and MRI parameters were collected. RESULTS: We identified 17 children with MS treated with cyclophosphamide. All but one had worsening of Expanded Disability Status Scale scores or multiple relapses prior to treatment initiation. Children were treated with one of three regimens: 1) induction therapy alone; 2) induction therapy with pulse maintenance therapy; or 3) pulse maintenance therapy alone. Treatment resulted in a reduction in relapse rate and stabilization of disability scores assessed 1 year after treatment initiation in the majority of patients. Longer follow-up was available for most cases. Cyclophosphamide was well tolerated in most patients. However, side effects included vomiting, transient alopecia, osteoporosis, and amenorrhea. One patient developed bladder carcinoma that was successfully treated. CONCLUSIONS: Cyclophosphamide is an option for the treatment of children with aggressive multiple sclerosis refractory to first-line therapies. Recommendations regarding patient selection, treatment administration, and monitoring are discussed.


Cyclophosphamide/administration & dosage , Immunosuppression Therapy/methods , Multiple Sclerosis/drug therapy , Adolescent , Age Factors , Age of Onset , Child , Cyclophosphamide/adverse effects , Disease Progression , Drug Administration Schedule , Drug Resistance/drug effects , Female , Glatiramer Acetate , Humans , Immunosuppression Therapy/adverse effects , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Interferon-beta/administration & dosage , Male , Mitoxantrone/administration & dosage , Multiple Sclerosis/immunology , Multiple Sclerosis/physiopathology , Peptides/administration & dosage , Retrospective Studies , Secondary Prevention , Sex Distribution , Treatment Outcome
7.
Neurology ; 72(11): 968-73, 2009 Mar 17.
Article En | MEDLINE | ID: mdl-19038851

BACKGROUND: Acute disseminated encephalomyelitis (ADEM) is typically a monophasic demyelinating disorder. However, a clinical presentation consistent with ADEM can also be the first manifestation of multiple sclerosis (MS), particularly in children. Quantitative analyses of MRI images from children with monophasic ADEM have yet to be compared with those from children with MS, and MRI criteria capable of distinguishing ADEM from MS at onset have yet to be derived. METHODS: A retrospective analysis of MRI scans obtained at first attack from 28 children subsequently diagnosed with MS and 20 children with ADEM was performed. T2/fluid-attenuated inversion recovery hyperintense lesions were quantified and categorized according to location, description, and size. T1-weighted images before and after administration of gadolinium were evaluated for the presence of black holes and for gadolinium enhancement. Mean lesion counts and qualitative features were compared between groups and analyzed to create a proposed diagnostic model. RESULTS: Total lesion number did not differentiate ADEM from MS, but periventricular lesions were more frequent in children with MS. Combined quantitative and qualitative analyses led to the following criteria to distinguish MS from ADEM: any two of 1) absence of a diffuse bilateral lesion pattern, 2) presence of black holes, and 3) presence of two or more periventricular lesions. Using these criteria, MS patients at first attack could be distinguished from monophasic ADEM patients with an 81% sensitivity and a 95% specificity. CONCLUSIONS: MRI diagnostic criteria are proposed that may be useful in differentiating children experiencing the first attack of multiple sclerosis from those with monophasic acute disseminated encephalomyelitis.


Encephalomyelitis, Acute Disseminated/diagnosis , Magnetic Resonance Imaging , Multiple Sclerosis/diagnosis , Adolescent , Brain/pathology , Child , Cohort Studies , Contrast Media , Diagnosis, Differential , Female , Gadolinium , Humans , Logistic Models , Male
8.
Neurology ; 72(11): 961-7, 2009 Mar 17.
Article En | MEDLINE | ID: mdl-19038852

BACKGROUND: MRI diagnostic criteria have not yet been adopted for pediatric multiple sclerosis (MS). MRI plays a pivotal role in supporting the diagnosis of MS in adults. We sought to quantitatively define the MRI features of pediatric MS, to determine features that distinguish MS from nondemyelinating relapsing childhood neurologic disorders, and to propose MRI criteria for lesion dissemination in space in children with MS. METHODS: A retrospective analysis of MRI scans from 38 children with clinically definite MS and 45 children with nondemyelinating diseases with relapsing neurologic deficits (migraine, systemic lupus erythematosus) was performed. For each scan, T2/FLAIR hyperintense lesions were quantified and categorized according to location and size. Mean lesion counts in specific locations were compared between groups to derive diagnostic criteria. Validation of the proposed criteria was performed using MRI scans from a second independent MS cohort (n = 21). RESULTS: MRI lesion location and size categories differed between children with MS and nondemyelinating controls with a medium to large effect size for most variables. The presence of at least two of the following-five or more lesions, two or more periventricular lesions, or one brainstem lesion-distinguished MS from other nondemyelinating disease controls with 85% sensitivity and 98% specificity. CONCLUSIONS: We propose modifications to the currently established McDonald MRI criteria for lesion dissemination in space that will enhance the diagnostic accuracy of these criteria for multiple sclerosis in children.


Magnetic Resonance Imaging/methods , Multiple Sclerosis/diagnosis , Adolescent , Adult , Age Factors , Aged , Brain/pathology , Child , Diagnosis, Differential , Encephalomyelitis, Acute Disseminated/pathology , Female , Humans , Image Interpretation, Computer-Assisted , Lupus Erythematosus, Systemic/pathology , Male , Middle Aged , Multiple Sclerosis/epidemiology , Multiple Sclerosis/pathology , Myelitis, Transverse/pathology , Nervous System Diseases/diagnosis , Nervous System Diseases/pathology , Observer Variation , Optic Neuritis/pathology , Regression Analysis , Retrospective Studies , Sample Size , Young Adult
9.
Mult Scler ; 14(9): 1157-74, 2008 Nov.
Article En | MEDLINE | ID: mdl-18805839

BACKGROUND AND OBJECTIVES: Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings. A systematic process for exclusion of alternative diagnoses has not been defined. An International Panel of MS experts developed consensus perspectives on MS differential diagnosis. METHODS: Using available literature and consensus, we developed guidelines for MS differential diagnosis, focusing on exclusion of potential MS mimics, diagnosis of common initial isolated clinical syndromes, and differentiating between MS and non-MS idiopathic inflammatory demyelinating diseases. RESULTS: We present recommendations for 1) clinical and paraclinical red flags suggesting alternative diagnoses to MS; 2) more precise definition of "clinically isolated syndromes" (CIS), often the first presentations of MS or its alternatives; 3) algorithms for diagnosis of three common CISs related to MS in the optic nerves, brainstem, and spinal cord; and 4) a classification scheme and diagnosis criteria for idiopathic inflammatory demyelinating disorders of the central nervous system. CONCLUSIONS: Differential diagnosis leading to MS or alternatives is complex and a strong evidence base is lacking. Consensus-determined guidelines provide a practical path for diagnosis and will be useful for the non-MS specialist neurologist. Recommendations are made for future research to validate and support these guidelines. Guidance on the differential diagnosis process when MS is under consideration will enhance diagnostic accuracy and precision.


Multiple Sclerosis/diagnosis , Practice Guidelines as Topic , Algorithms , Diagnosis, Differential , Humans
10.
Neurology ; 61(12): 1779-82, 2003 Dec 23.
Article En | MEDLINE | ID: mdl-14694046

OBJECTIVE: To establish the incidence of muscle weakness in critically ill children. METHODS: Neuromuscular examinations were performed in 830 children without identified antecedent or acute neuromuscular disease (age 3 months to 17 years 11 months) admitted for >24 hours to a pediatric intensive care unit (ICU) over a 1-year period. RESULTS: Fourteen of 830 (1.7%) patients had generalized weakness. Four failed repeated attempts to extubate. Multiple organ dysfunction occurred in 11 patients and sepsis in 9. Most children received corticosteroids, neuromuscular blocking agents, or aminoglycoside antibiotics. Eight of the 14 children were solid organ or bone marrow transplant recipients. Muscle biopsy showed evidence of acute quadriplegic myopathy in all three patients in whom biopsy was performed. Three patients died. In survivors, significant weakness persisted for 3 to 12 months following ICU discharge. CONCLUSIONS: Muscle weakness is an infrequent but significant feature of critical illness in children. Transplant recipients seem to be at particular risk.


Critical Illness/mortality , Muscle Weakness/diagnosis , Muscle Weakness/mortality , Adolescent , Child , Child, Preschool , Comorbidity , Electrodiagnosis , Female , Humans , Incidence , Infant , Intensive Care Units, Pediatric/statistics & numerical data , Length of Stay/statistics & numerical data , Male , Multiple Organ Failure/mortality , Muscle Weakness/therapy , Muscle, Skeletal/pathology , Muscular Diseases/pathology , Ontario/epidemiology , Prognosis , Prospective Studies , Sepsis/mortality
11.
Pediatr Neurol ; 25(1): 59-61, 2001 Jul.
Article En | MEDLINE | ID: mdl-11483398

Two brothers with a painful neuropathy as a component of late-onset GM2 gangliosidosis of the Sandhoff type are presented. A dramatic response of the severe dysesthesias to amitriptyline and gabapentin is described. Symptomatic sensory neuropathy may be a component of late-onset GM2 gangliosidosis.


Amines , Cyclohexanecarboxylic Acids , Gangliosidoses, GM2/complications , Gangliosidoses, GM2/diagnosis , Paresthesia/etiology , Sandhoff Disease/complications , gamma-Aminobutyric Acid , Acetates/therapeutic use , Adolescent , Amitriptyline/therapeutic use , Analgesics/therapeutic use , Antidepressive Agents, Tricyclic/therapeutic use , Drug Therapy, Combination , Evoked Potentials, Somatosensory , Foot/physiopathology , Gabapentin , Humans , Male , Paresthesia/drug therapy , Sandhoff Disease/drug therapy , Treatment Outcome
12.
Pediatr Neurol ; 24(4): 257-63, 2001 Apr.
Article En | MEDLINE | ID: mdl-11377099

The dynamic and critical role of intermediate filaments in muscle is highlighted by myopathies characterized by aberrant accumulation of intermediate filaments. In some affected patients, mutations in genes encoding intermediate filaments that are expressed in muscle have been confirmed. The importance of intermediate filaments in muscle is further strengthened by murine models in which genetically designed intermediate filament mutations are expressed, leading to progressive skeletal or cardioskeletal myopathy in affected mice. In this article the intermediate filaments expressed in muscle are reviewed, and the clinical and pathologic features of myopathies known to relate to intermediate filaments are described. With the increasing awareness of intermediate filaments in muscle and the rapid advances in genetic investigation, it is likely that the list of intermediate filament-related myopathies will expand.


Intermediate Filaments/genetics , Mutation , Myopathies, Structural, Congenital/genetics , Nerve Tissue Proteins , Adult , Animals , Avian Proteins , Child , Desmin/genetics , Humans , Intermediate Filament Proteins/genetics , Lamins , Mice , Mice, Knockout , Muscle Proteins/genetics , Myopathies, Structural, Congenital/metabolism , Myopathies, Structural, Congenital/pathology , Nestin , Nuclear Proteins/genetics , Plectin , Vimentin/genetics
13.
Neurology ; 54(5): 1033-41, 2000 Mar 14.
Article En | MEDLINE | ID: mdl-10720271

OBJECTIVE: To study the expression of the small heat shock protein, alphaB-crystallin (alphaBC), in inclusion body myositis (IBM). BACKGROUND: In humans, alphaBC is constitutively expressed in the eye lens, muscle, and heart, but not in lymphoid tissues. Induced expression of alphaBC occurs under metabolic stress, in virus-infected lymphocytes, and in degenerative brain lesions, including neurofibrillary tangles and senile plaques in AD. The previously reported pathologic similarities between AD and IBM prompted us to study alphaBC expression in IBM. METHODS: Immunolocalization of alphaBC in muscle of 11 patients with IBM, 50 patients with other muscle diseases, and 4 controls; and quantitative analysis of the frequency of fibers with 1) increased alphaBC expression in IBM and polymyositis and 2) structural abnormality (vacuolated, non-necrotic and invaded by mononuclear cells, Congo red-positive, SMI-31 positive, and ubiquitin positive) in IBM. RESULTS: We detected enhanced expression of alphaBC not only in all structurally abnormal IBM fibers, but also, and with severalfold higher frequency, in IBM fibers without significant structural abnormality (X fibers) (p values in paired t-tests < 0.001). We also found enhanced alphaBC in abnormal fibers in other diseases; X fibers, however, were extremely sparse or absent, except in two atypical cases of polymyositis refractory to immunotherapy. CONCLUSION: That the X fibers are much more frequent than the structurally abnormal fibers in IBM points to a pathogenic stressor acting upstream to the development of structural abnormalities. The identification of this stressor is now of paramount importance for deciphering the enigma of IBM.


Crystallins/analysis , Myositis, Inclusion Body/pathology , Adult , Aged , Child , Child, Preschool , Female , Humans , Immunohistochemistry , Infant , Male , Middle Aged , Muscles/pathology
14.
J Neuropathol Exp Neurol ; 58(8): 832-46, 1999 Aug.
Article En | MEDLINE | ID: mdl-10446808

Plectin, an intermediate filament linking protein, is normally associated with the sarcolemma, nuclear membrane, and intermyofibrillar network in muscle, and with hemisdesmosomes in skin. A 20-year-old female with epidermolysis bullosa simplex since birth had progressive ocular, facial, limb, and trunkal weakness and fatigability since age 9, fivefold CK elevation, a 25% decrement with myopathic motor unit potentials and increased electrical irritability on electromyography, and no anti-acetylcholine receptor (AChR) antibodies. Plectin expression was absent in muscle and severe plectin deficiency was noted in skin. Morphologic studies revealed necrotic and regenerating fibers and a wide spectrum of ultrastructural abnormalities: large accumulations of heterochromatic and lobulated nuclei, rare apoptotic nuclei, numerous cytoplasmic and few intranuclear nemaline rods, disarrayed myofibrils, thick-filament loss, vacuolar change, and pathologic alterations in membranous organelles. Many endplates (EPs) had an abnormal configuration with chains of small regions over the fiber surface and a few displayed focal degeneration of the junctional folds. The EP AChR content was normal. In vitro electrophysiologic studies showed normal quantal release by nerve impulse, small miniature EP potentials, and fetal as well as adult AChR channels at the EP. Our findings support the notion that plectin is essential for the structural integrity of muscle and skin, and for normal neuromuscular transmission.


Epidermolysis Bullosa Simplex/metabolism , Intermediate Filament Proteins/deficiency , Intestinal Pseudo-Obstruction/metabolism , Muscle Weakness/metabolism , Adult , Electrophysiology , Epidermolysis Bullosa Simplex/pathology , Female , Humans , Immunohistochemistry , Intestinal Pseudo-Obstruction/pathology , Motor Endplate/metabolism , Motor Endplate/pathology , Motor Endplate/physiopathology , Motor Endplate/ultrastructure , Muscle Fibers, Skeletal/pathology , Muscle Fibers, Skeletal/ultrastructure , Muscle Weakness/pathology , Muscles/metabolism , Muscles/pathology , Muscles/ultrastructure , Myofibrils/pathology , Myofibrils/ultrastructure , Plectin , Receptors, Cholinergic/drug effects , Receptors, Cholinergic/metabolism , Skin/pathology , Skin/ultrastructure , Syndrome
15.
J Child Neurol ; 14(2): 83-7, 1999 Feb.
Article En | MEDLINE | ID: mdl-10073429

Cardiac involvement has not been a reported feature of congenital fiber-type disproportion myopathy. We describe two children, aged 13 years and 1 year, respectively, who presented with serious cardiac symptomatology in conjunction with congenital fiber-type disproportion. One child developed dilated cardiomyopathy and medically intractable congestive heart failure necessitating cardiac transplantation at the age of 13 years. The second (unrelated) child developed atrial fibrillation with rapid atrioventricular conduction requiring treatment with digoxin. Skeletal muscle biopsy findings in both children showed congenital fiber-type disproportion with no evidence of a structural, dystrophic, or metabolic myopathy. Adenosine triphosphatase (ATPase) reacted sections showed type I hypotrophy with a predominance of type I fibers, confirmed by histogram analysis. Examination of the heart from patient 1 at the time of transplantation confirmed dilated cardiomyopathy with hypertrophic myocardiocytes. Although cardiomyopathy is commonly associated with other childhood myopathies, to our knowledge it has not been a feature in reported cases of congenital fiber-type disproportion. We recommend close cardiac assessment, with annual electrocardiograms, of children with congenital fiber-type disproportion.


Cardiomyopathy, Dilated/complications , Myopathies, Nemaline/complications , Biopsy , Cardiomyopathy, Dilated/surgery , Female , Heart Transplantation , Humans , Infant , Infant, Newborn , Male , Muscle, Skeletal/pathology , Myopathies, Nemaline/diagnosis
16.
Pediatr Neurol ; 10(4): 335-7, 1994 Jun.
Article En | MEDLINE | ID: mdl-8068164

Two children are reported who are notable exceptions to the rule of early mortality reported for neonates with severe nemaline rod myopathy. Their conditions improved progressively from birth with full pediatric critical care unit support. They achieved respiratory independence at 22 months and 15 months and now at ages 29 months and 17 months, respectively, they are cognitively normal and demonstrating progressive improvement in muscle strength.


Critical Care , Intensive Care Units, Neonatal , Myopathies, Nemaline/mortality , Child Development , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Motor Skills , Muscles/pathology , Myopathies, Nemaline/pathology , Myopathies, Nemaline/therapy , Occupational Therapy , Physical Therapy Modalities , Prognosis , Ventilator Weaning
...